A Double-Blind, Randomized, Phase 2 Trial of Capecitabine Plus Enzastaurin Versus Capecitabine Plus Placebo in Patients With Metastatic or Recurrent Breast Cancer Previously Treated With an Anthracycline and a Taxane.

Trial Profile

A Double-Blind, Randomized, Phase 2 Trial of Capecitabine Plus Enzastaurin Versus Capecitabine Plus Placebo in Patients With Metastatic or Recurrent Breast Cancer Previously Treated With an Anthracycline and a Taxane.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2010

At a glance

  • Drugs Capecitabine; Enzastaurin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
    • 29 Sep 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Primary endpoint 'Progression free survival duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top